NZ542738A - Antineoplastic combinations comprising temsirolimus or everolimus and an aromatase inhibitor - Google Patents
Antineoplastic combinations comprising temsirolimus or everolimus and an aromatase inhibitorInfo
- Publication number
- NZ542738A NZ542738A NZ542738A NZ54273804A NZ542738A NZ 542738 A NZ542738 A NZ 542738A NZ 542738 A NZ542738 A NZ 542738A NZ 54273804 A NZ54273804 A NZ 54273804A NZ 542738 A NZ542738 A NZ 542738A
- Authority
- NZ
- New Zealand
- Prior art keywords
- aromatase inhibitor
- temsirolimus
- everolimus
- combinations
- antineoplastic combinations
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 2
- 229960000235 temsirolimus Drugs 0.000 title abstract 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
- 229960005167 everolimus Drugs 0.000 title 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- HKVAMNSJSFKALM-CPXURSODSA-N everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-CPXURSODSA-N 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003881 letrozole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45228903P | 2003-03-05 | 2003-03-05 | |
| PCT/US2004/006354 WO2004078133A2 (en) | 2003-03-05 | 2004-03-01 | Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ542738A true NZ542738A (en) | 2009-02-28 |
Family
ID=32962706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ542738A NZ542738A (en) | 2003-03-05 | 2004-03-01 | Antineoplastic combinations comprising temsirolimus or everolimus and an aromatase inhibitor |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040176339A1 (enExample) |
| EP (1) | EP1603561A2 (enExample) |
| JP (1) | JP2006519862A (enExample) |
| KR (1) | KR20050109965A (enExample) |
| CN (1) | CN1756549A (enExample) |
| AR (1) | AR043403A1 (enExample) |
| AU (1) | AU2004218439A1 (enExample) |
| BR (1) | BRPI0408024A (enExample) |
| CA (1) | CA2516353A1 (enExample) |
| CR (1) | CR7942A (enExample) |
| EC (1) | ECSP056001A (enExample) |
| MX (1) | MXPA05009246A (enExample) |
| NI (1) | NI200500148A (enExample) |
| NO (1) | NO20054133L (enExample) |
| NZ (1) | NZ542738A (enExample) |
| RU (1) | RU2355399C2 (enExample) |
| TW (1) | TW200529829A (enExample) |
| UA (1) | UA83484C2 (enExample) |
| WO (1) | WO2004078133A2 (enExample) |
| ZA (1) | ZA200508029B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
| KR20060052880A (ko) * | 2003-07-25 | 2006-05-19 | 와이어쓰 | 동결건조된 ｃｃｉ- 779 제형 |
| DE602004011398T2 (de) * | 2004-01-08 | 2009-01-15 | Wyeth | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 |
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
| EP1804779A1 (en) * | 2004-10-28 | 2007-07-11 | Wyeth | Use of an mtor inhibitor in treatment of uterine leiomyoma |
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| EP3488866A1 (en) * | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| PT2275103E (pt) * | 2005-11-21 | 2014-07-24 | Novartis Ag | Inibidores de mtor para o tratamento de tumores endócrinos |
| DE102006008074B4 (de) * | 2006-02-22 | 2013-08-14 | RUHR-UNIVERSITäT BOCHUM | Behandlung von Krebs mit Geruchsrezeptor-Liganden |
| DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| CA2743242A1 (en) * | 2008-11-11 | 2010-05-20 | Eli Lilly And Company | P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
| WO2010118419A2 (en) | 2009-04-10 | 2010-10-14 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| ES2694582T3 (es) * | 2011-01-31 | 2018-12-21 | Lucolas-M.D. Ltd. | Combinaciones de inhibidores de aromatasa y antioxidantes |
| US9682066B2 (en) * | 2012-12-04 | 2017-06-20 | University Of Cincinnati | Methods of treating primary brain tumors by administering letrozole |
| WO2015014284A1 (zh) * | 2013-07-31 | 2015-02-05 | 北京盛诺基医药科技有限公司 | 一种乳腺癌的治疗方法 |
| CN106061482A (zh) * | 2013-10-08 | 2016-10-26 | 拉姆医疗公司 | 用于治疗淋巴管平滑肌瘤病的雷帕霉素 |
| NZ724756A (en) | 2014-04-04 | 2023-07-28 | Ai Therapeutics Inc | An inhalable rapamycin formulation for treating age-related conditions |
| CA2963085C (en) | 2014-10-07 | 2023-02-21 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6A (en) * | 1836-08-10 | Thomas Blanchard | Machine for forming end pieces of plank blocks for ships | |
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5561138A (en) * | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| ATE278421T1 (de) * | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| CN1551767A (zh) * | 2001-02-19 | 2004-12-01 | ��˹��ŵ�� | 癌症的治疗 |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| ATE406892T1 (de) * | 2001-04-06 | 2008-09-15 | Wyeth Corp | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| US20030008923A1 (en) * | 2001-06-01 | 2003-01-09 | Wyeth | Antineoplastic combinations |
| PL367267A1 (en) * | 2001-06-01 | 2005-02-21 | Wyeth | Antineoplastic combinations |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2004
- 2004-01-03 UA UAA200509283A patent/UA83484C2/uk unknown
- 2004-02-26 AR ARP040100603A patent/AR043403A1/es unknown
- 2004-03-01 EP EP04716169A patent/EP1603561A2/en not_active Withdrawn
- 2004-03-01 US US10/790,488 patent/US20040176339A1/en not_active Abandoned
- 2004-03-01 NZ NZ542738A patent/NZ542738A/xx unknown
- 2004-03-01 RU RU2005130767/14A patent/RU2355399C2/ru not_active IP Right Cessation
- 2004-03-01 AU AU2004218439A patent/AU2004218439A1/en not_active Withdrawn
- 2004-03-01 WO PCT/US2004/006354 patent/WO2004078133A2/en not_active Ceased
- 2004-03-01 KR KR1020057016528A patent/KR20050109965A/ko not_active Ceased
- 2004-03-01 BR BRPI0408024-6A patent/BRPI0408024A/pt not_active IP Right Cessation
- 2004-03-01 MX MXPA05009246A patent/MXPA05009246A/es not_active Application Discontinuation
- 2004-03-01 CA CA002516353A patent/CA2516353A1/en not_active Abandoned
- 2004-03-01 JP JP2006509002A patent/JP2006519862A/ja active Pending
- 2004-03-01 CN CNA200480005869XA patent/CN1756549A/zh active Pending
- 2004-03-02 TW TW093105371A patent/TW200529829A/zh unknown
-
2005
- 2005-08-12 CR CR7942A patent/CR7942A/es not_active Application Discontinuation
- 2005-09-01 NI NI200500148A patent/NI200500148A/es unknown
- 2005-09-05 EC EC2005006001A patent/ECSP056001A/es unknown
- 2005-09-06 NO NO20054133A patent/NO20054133L/no not_active Application Discontinuation
- 2005-10-04 ZA ZA200508029A patent/ZA200508029B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054133D0 (no) | 2005-09-06 |
| WO2004078133A3 (en) | 2004-11-11 |
| NI200500148A (es) | 2006-03-30 |
| AU2004218439A1 (en) | 2004-09-16 |
| ZA200508029B (en) | 2007-04-25 |
| CR7942A (es) | 2006-02-07 |
| RU2355399C2 (ru) | 2009-05-20 |
| MXPA05009246A (es) | 2005-10-19 |
| JP2006519862A (ja) | 2006-08-31 |
| US20040176339A1 (en) | 2004-09-09 |
| WO2004078133A2 (en) | 2004-09-16 |
| CN1756549A (zh) | 2006-04-05 |
| NO20054133L (no) | 2005-10-03 |
| AR043403A1 (es) | 2005-07-27 |
| TW200529829A (en) | 2005-09-16 |
| KR20050109965A (ko) | 2005-11-22 |
| WO2004078133A8 (en) | 2005-09-01 |
| UA83484C2 (uk) | 2008-07-25 |
| EP1603561A2 (en) | 2005-12-14 |
| CA2516353A1 (en) | 2004-09-16 |
| BRPI0408024A (pt) | 2006-02-14 |
| ECSP056001A (es) | 2006-01-27 |
| RU2005130767A (ru) | 2006-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05009246A (es) | Combinaciones antineoplasicas. | |
| EP2671581B8 (en) | Compositions and methods for treating cancer | |
| IL202155A (en) | Medicines containing 40-o- (2-hydroxyethyl) -rapamycin and aromatase inhibitor, and their use in the preparation of drugs for the treatment of solid breast tumors | |
| AU2003230750A1 (en) | Compositions and methods for treating cancer | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| AU2003291356A1 (en) | Methods and compositions for treating cancer using proteasome inhibitors | |
| AU2003900747A0 (en) | Diagnosis and treatment of pancreatic cancer | |
| SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
| GB2430935A (en) | Tetrapeptide analogs | |
| SG150559A1 (en) | Antineoplastic combinations of cci-779 and rituximab | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| EP1610806A4 (en) | METHOD FOR THE TREATMENT OF CANCER WITH AZASPIRANE COMPOSITIONS | |
| WO2005000204A3 (en) | Pancreatic cancer treatment | |
| EP1349485A4 (en) | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA | |
| WO2006060819A3 (en) | Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells | |
| AU2003298708A1 (en) | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| AU2003225461A8 (en) | Composition and method for supporting cancer treatments | |
| AU2001249493A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| WO2002024179A3 (en) | Method for reducing toxicity of combined chemotherapies | |
| EP1273296A3 (en) | Combination chemotherapy | |
| AU2004281077A1 (en) | Methods and agents for the treatment of cancer | |
| MY136436A (en) | Cci-779 for treating mantle cell lymphoma | |
| AU2003285883A1 (en) | Methods and compositions for determining risk of treatment toxicity | |
| PT1618116E (pt) | Complexos de ruténio(ii) para o tratamento de tumores | |
| WO2005023199A3 (en) | Socs-3 promoter methylation in cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |